<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Monoclonal antibodies, specific for antigens expressed on lymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, which have been conjugated to toxins such as ricin, hold promise in the therapy of childhood <z:hpo ids='HP_0001909'>leukemia</z:hpo> and <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Anti-B4-blocked ricin (anti-B4-bR) is such an agent, and a phase I study of this agent was conducted in children with relapsed or refractory B-lineage <z:hpo ids='HP_0001909'>leukemia</z:hpo> and <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Anti-B4-bR was given as two 7-day continuous infusions separated by 7 days </plain></SENT>
<SENT sid="3" pm="."><plain>Twenty patients were enrolled and 19 received the drug </plain></SENT>
<SENT sid="4" pm="."><plain>Two dosage levels (30 and 40 microg/kg per day) were evaluated </plain></SENT>
<SENT sid="5" pm="."><plain>Forty micrograms per kilogram per day was the maximally tolerated dose </plain></SENT>
<SENT sid="6" pm="."><plain>Dose-limiting toxicity was <z:e sem="disease" ids="C0343084" disease_type="Disease or Syndrome" abbrv="AVLS">capillary leak syndrome</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Grade 3 reversible elevation in transaminases was also encountered </plain></SENT>
<SENT sid="8" pm="."><plain>Human antimouse antibodies or human antiricin antibodies were detected in five patients </plain></SENT>
<SENT sid="9" pm="."><plain>No complete remissions or partial remissions were seen </plain></SENT>
</text></document>